Effects of neonatal treatment with diethylstilbestrol and 17 alpha-hydroxyprogesterone caproate on in vitro pituitary prolactin secretion.
The effects of neonatal hormone treatment with diethylstilbestrol (DES) and 17 alpha-hydroxyprogesterone caproate (HPC) on days 1-5 of life on serum prolactin (PRL) levels and 3H-PRL synthesis and release were studied in C3H/MTV+ mice at 2, 4, 6, 8 and 10 weeks of age. Neonatal treatment of mice with 2.5 micrograms/day DES was the only treatment that affected the developmental pattern of serum PRL levels. Serum PRL levels were significantly decreased at 6 wks of age with this dose of DES. Neonatal treatment with 2.5 micrograms/day DES and 150 micrograms/day HPC affected the developmental pattern of H-PRL synthesis by the pituitary. At 10 wks of age 3H-PRL synthesis was significantly decreased by these doses of DES and HPC. The percent of 3H-PRL released did not differ between neonatally hormone treated and control animals, suggesting that neonatal treatment affected mechanisms that regulate PRL synthesis but not those that regulate release.
D019326:17-alpha-Hydroxyprogesterone; D000818:Animals; D000831:Animals, Newborn / Q000378:metabolism*; D004054:Diethylstilbestrol / Q000494:pharmacology*; D005260:Female; D006908:Hydroxyprogesterones / Q000494:pharmacology*; D066298:In Vitro Techniques; D051379:Mice; D008809:Mice, Inbred C3H; D010902:Pituitary Gland / Q000378:metabolism*; D011388:Prolactin / Q000096:biosynthesis / Q000378:metabolism*
D006908:Hydroxyprogesterones; D019326:17-alpha-Hydroxyprogesterone; D004054:Diethylstilbestrol; D011388:Prolactin